Aliskiren - Mode of action and preclinical data

Journal of Molecular Medicine

Volumn 86, Issue 6, 2008, Pages 659-662

  Müller, Dominik N ^a   Derer, Wolfgang ^b,c   Dechend, Ralf ^b,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FRANZ VOLHARD CLINIC   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

Hypertension; Renin; Renin angiotensin system

Indexed keywords

ALISKIREN; EPLERENONE; LOSARTAN; PERINDOPRIL; SPIRONOLACTONE; VALSARTAN;

ALBUMINURIA; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; GLOMERULOSCLEROSIS; HEART INJURY; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY INJURY; NONHUMAN; PLASMA RENIN ACTIVITY; REVIEW;

AMIDES; ANIMALS; DRUG EVALUATION, PRECLINICAL; FUMARATES; HUMANS; RENIN;

EID: 43449112039     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0330-6     Document Type: Review

References (18)

1. Azizi M (2006) Renin inhibition. Curr Opin Nephrol Hypertens 15(5):505-510
2. Muller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1(2):221-228
3. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH (1997) Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10(1):1-8
4. Kehoe B, Keeton GR, Hill C (1986) Elevated plasma renin activity associated with renal dysfunction. Nephron 44(1):51-57
5. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T (2002) Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 252(5):430-439
6. Alderman MH, Cohen HW, Sealey JE, Laragh JH (2004) Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 17(1):1-7
7. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S, Fukamizu A, Mullins J, Murakami K (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 89(16):7806-7810
8. Wellner M, Dechend R, Park JK, Shagdarsuren E, Al-Saadi N, Kirsch T, Gratze P, Schneider W, Meiners S, Fiebeler A, Haller H, Luft FC, Muller DN (2005) Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics 20(3):256-267
9. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46(3):569-576
10. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN (2005) Complement activation in angiotensin II-induced organ damage. Circ Res 97(7):716-724
11. Dechend R, Shagdarsuren E, Gratze P, Fiebeler A, Pilz B, Meiners S, Derer W, Feldman DL, Webb R, Muller DN (2007) Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst 8(2):81-84
12. Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, Park JK, Gapelyuk A, Schwarz I, Zacharzowsky UB, Plehm R, Safak E, Heuser A, Schirdewan A, Luft FC, Schunck WH, Muller DN (2008) Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 51(2):540-546
13. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN (2005) Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111(23):3087-3094
14. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC (2001) Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37(2 Part 2):787-793
15. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109(22):2792-2800
16. Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39(1):E1-E8
17. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50(11):2398-2404
18. Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Muller P, Jennings GT, Bachmann MF (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25(1):63-72